Page 3 - Kodiak Sciences News Today

/PRNewswire/ -- The "Age-Related Macular Degeneration - Seven-Market Drug Forecast and Market Analysis - Update" report has been added to...

/PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative...

PALO ALTO, Calif., Jan. 4, 2024 /PRNewswire/ -- Kodiak Sciences Inc. , a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high...

Kodiak Sciences Inc. , a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the 42nd Annual J.P....

Vericel (NASDAQ:VCEL – Get Free Report) and Kodiak Sciences (NASDAQ:KOD – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk. Profitability This table compares Vericel and Kodiak Sciences’ […]

Kodiak Sciences Inc. (NASDAQ:KOD – Get Free Report) has been assigned a consensus recommendation of “Reduce” from the six research firms that are covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and one has assigned a buy recommendation to the […]

Shares of Kodiak Sciences Inc. (NASDAQ:KOD – Get Free Report) have been given an average recommendation of “Reduce” by the six ratings firms that are presently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, three have issued a hold rating and one has assigned a buy rating […]

The Goldman Sachs Group reaffirmed their sell rating on shares of Kodiak Sciences (NASDAQ:KOD – Free Report) in a research note published on Monday, MarketBeat reports. The Goldman Sachs Group currently has a $2.00 price target on the stock. Separately, Capital One Financial raised Kodiak Sciences from an equal weight rating to an overweight rating […]

TODAY’S GAME PLAN: from the trading desk, this is not research DATA/HEADLINES 11:00ET NY Fed 1-Yr Inflation Expectations; 11:30ET 3 Year Note Auction; 1:00ET 10 Year Note Auction Tuesday: Japan producer prices, India inflation, Brazil inflation, UK unemployment, US inflation TODAY’S HIGHLIGHTS: Zelenskiy travels to the US to discuss Ukraine’s urgent defense needs with President

Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition.